Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cell Genesys GVAX Prostate Cancer Vaccine Will Begin Phase III Under Special Protocol Assessment

This article was originally published in The Pink Sheet Daily

Executive Summary

Clinical trial program will attempt to demonstrate superiority over taxane chemotherapy in treating hormone-refractory metastatic prostate cancer patients. Cell Genesys hopes to highlight tolerability, dosing convenience of vaccine if approved.

You may also be interested in...



Cell Genesys Set To License Phase III Cancer Immunotherapeutic; Final Data Likely In 2009

Interim data monitoring committee analysis raised no flags on the first of two trials of GVAX therapy in prostate cancer, CEO Sherwin reports.

Cell Genesys Set To License Phase III Cancer Immunotherapeutic; Final Data Likely In 2009

Interim data monitoring committee analysis raised no flags on the first of two trials of GVAX therapy in prostate cancer, CEO Sherwin reports.

Medarex To Start Pivotal Trial Of MDX-010/Cancer Vaccine Combo For Melanoma

The company plans a Subpart E filing as early as 2006 based on response rate data from the Phase III study, designed under a special protocol assessment with FDA. The immune-boosting MDX-010/MDX-1349 combination trial will start enrolling patients in September.

Related Content

Topics

UsernamePublicRestriction

Register

PS059362

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel